TVTX Quote, Financials, Valuation and Earnings

Iovance Biotherapeutics, Inc. has a net margin of 15.59% compared to Travere Therapeutics, Inc.'s net margin of -135.28%. Travere Therapeutics, Inc.'s return on equity of -263.9% beat Iovance Biotherapeutics, Inc.'s return on equity of -54.43%.

Travere Therapeutics, Inc. has a consensus price target of $42.3571, signalling upside risk potential of 44.32%. On the other hand Iovance Biotherapeutics, Inc. has an analysts' consensus of $9.11 which suggests that it could grow by 219.69%. Given that Iovance Biotherapeutics, Inc. has higher upside potential than Travere Therapeutics, Inc., analysts believe Iovance Biotherapeutics, Inc. is more attractive than Travere Therapeutics, Inc..

Travere Therapeutics, Inc. has a beta of 0.827, which suggesting that the stock is 17.33% less volatile than S&P 500. In comparison Iovance Biotherapeutics, Inc. has a beta of 0.765, suggesting its less volatile than the S&P 500 by 23.531%.

Travere Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Iovance Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Travere Therapeutics, Inc. pays -- of its earnings as a dividend. Iovance Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Travere Therapeutics, Inc. quarterly revenues are $164.9M, which are larger than Iovance Biotherapeutics, Inc. quarterly revenues of $67.5M. Travere Therapeutics, Inc.'s net income of $25.7M is higher than Iovance Biotherapeutics, Inc.'s net income of -$91.3M. Notably, Travere Therapeutics, Inc.'s price-to-earnings ratio is -- while Iovance Biotherapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Travere Therapeutics, Inc. is 6.11x versus 3.77x for Iovance Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Intuitive Surgical, Inc. has a net margin of 15.59% compared to Travere Therapeutics, Inc.'s net margin of 27.89%. Travere Therapeutics, Inc.'s return on equity of -263.9% beat Intuitive Surgical, Inc.'s return on equity of 16.59%.

Travere Therapeutics, Inc. has a consensus price target of $42.3571, signalling upside risk potential of 44.32%. On the other hand Intuitive Surgical, Inc. has an analysts' consensus of $611.82 which suggests that it could grow by 22.48%. Given that Travere Therapeutics, Inc. has higher upside potential than Intuitive Surgical, Inc., analysts believe Travere Therapeutics, Inc. is more attractive than Intuitive Surgical, Inc..

Travere Therapeutics, Inc. has a beta of 0.827, which suggesting that the stock is 17.33% less volatile than S&P 500. In comparison Intuitive Surgical, Inc. has a beta of 1.653, suggesting its more volatile than the S&P 500 by 65.303%.

Travere Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Intuitive Surgical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Travere Therapeutics, Inc. pays -- of its earnings as a dividend. Intuitive Surgical, Inc. pays out -- of its earnings as a dividend.

Travere Therapeutics, Inc. quarterly revenues are $164.9M, which are smaller than Intuitive Surgical, Inc. quarterly revenues of $2.9B. Travere Therapeutics, Inc.'s net income of $25.7M is lower than Intuitive Surgical, Inc.'s net income of $799.5M. Notably, Travere Therapeutics, Inc.'s price-to-earnings ratio is -- while Intuitive Surgical, Inc.'s PE ratio is 63.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Travere Therapeutics, Inc. is 6.11x versus 18.00x for Intuitive Surgical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Ligand Pharmaceuticals, Inc. has a net margin of 15.59% compared to Travere Therapeutics, Inc.'s net margin of 10.18%. Travere Therapeutics, Inc.'s return on equity of -263.9% beat Ligand Pharmaceuticals, Inc.'s return on equity of 5.72%.

Travere Therapeutics, Inc. has a consensus price target of $42.3571, signalling upside risk potential of 44.32%. On the other hand Ligand Pharmaceuticals, Inc. has an analysts' consensus of $243.44 which suggests that it could grow by 30.77%. Given that Travere Therapeutics, Inc. has higher upside potential than Ligand Pharmaceuticals, Inc., analysts believe Travere Therapeutics, Inc. is more attractive than Ligand Pharmaceuticals, Inc..

Travere Therapeutics, Inc. has a beta of 0.827, which suggesting that the stock is 17.33% less volatile than S&P 500. In comparison Ligand Pharmaceuticals, Inc. has a beta of 1.182, suggesting its more volatile than the S&P 500 by 18.151%.

Travere Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ligand Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Travere Therapeutics, Inc. pays -- of its earnings as a dividend. Ligand Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Travere Therapeutics, Inc. quarterly revenues are $164.9M, which are larger than Ligand Pharmaceuticals, Inc. quarterly revenues of $115.5M. Travere Therapeutics, Inc.'s net income of $25.7M is lower than Ligand Pharmaceuticals, Inc.'s net income of $117.3M. Notably, Travere Therapeutics, Inc.'s price-to-earnings ratio is -- while Ligand Pharmaceuticals, Inc.'s PE ratio is 89.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Travere Therapeutics, Inc. is 6.11x versus 14.58x for Ligand Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Plus Therapeutics, Inc. has a net margin of 15.59% compared to Travere Therapeutics, Inc.'s net margin of -316.61%. Travere Therapeutics, Inc.'s return on equity of -263.9% beat Plus Therapeutics, Inc.'s return on equity of --.

Travere Therapeutics, Inc. has a consensus price target of $42.3571, signalling upside risk potential of 44.32%. On the other hand Plus Therapeutics, Inc. has an analysts' consensus of $5.50 which suggests that it could grow by 1778.42%. Given that Plus Therapeutics, Inc. has higher upside potential than Travere Therapeutics, Inc., analysts believe Plus Therapeutics, Inc. is more attractive than Travere Therapeutics, Inc..

Travere Therapeutics, Inc. has a beta of 0.827, which suggesting that the stock is 17.33% less volatile than S&P 500. In comparison Plus Therapeutics, Inc. has a beta of 0.886, suggesting its less volatile than the S&P 500 by 11.364%.

Travere Therapeutics, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Plus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Travere Therapeutics, Inc. pays -- of its earnings as a dividend. Plus Therapeutics, Inc. pays out -- of its earnings as a dividend.

Travere Therapeutics, Inc. quarterly revenues are $164.9M, which are larger than Plus Therapeutics, Inc. quarterly revenues of $1.4M. Travere Therapeutics, Inc.'s net income of $25.7M is higher than Plus Therapeutics, Inc.'s net income of -$4.4M. Notably, Travere Therapeutics, Inc.'s price-to-earnings ratio is -- while Plus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Travere Therapeutics, Inc. is 6.11x versus 4.69x for Plus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.